<SEC-DOCUMENT>0001104659-13-000035.txt : 20130102
<SEC-HEADER>0001104659-13-000035.hdr.sgml : 20130101
<ACCEPTANCE-DATETIME>20130102085922
ACCESSION NUMBER:		0001104659-13-000035
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20121228
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20130102
DATE AS OF CHANGE:		20130102

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OvaScience, Inc.
		CENTRAL INDEX KEY:			0001544227
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				451472564
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-54647
		FILM NUMBER:		13500241

	BUSINESS ADDRESS:	
		STREET 1:		215 FIRST STREET
		STREET 2:		SUITE 240
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		617-902-0682

	MAIL ADDRESS:	
		STREET 1:		215 FIRST STREET
		STREET 2:		SUITE 240
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a12-30363_18k.htm
<DESCRIPTION>8-K
<TEXT>


<html>
<head>


  </head>
<body lang="EN-US">
<div style="font-family:Times New Roman;">
<div style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 3.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">UNITED STATES</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">WASHINGTON, D.C. 20549</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">
<hr size="1" width="25%" noshade color="black" align="center">
</font></b></div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">FORM 8-K</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">CURRENT REPORT<br> Pursuant to Section 13 or 15(d) of the</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">Securities Exchange Act of 1934</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date of report (Date of earliest event reported):&#160; <b>December 28, 2012</b></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">OvaScience, Inc.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Exact Name of Registrant as Specified in Charter)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Delaware</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">000-54647</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">45-1472564</font></b></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(State or Other Jurisdiction</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Commission</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(IRS Employer</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">of Incorporation)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">File Number)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Identification No.)</font></p>    </td>   </tr>  </table>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">215 First Street, Suite 240, Cambridge, MA</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">02142</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Address of Principal Executive Offices)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Zip Code)</font></p>    </td>   </tr>  </table>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Registrant&#146;s telephone number, including area code:&#160; <b>(617) 500-2802</b></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Former Name or Former Address, if Changed Since Last Report)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">&#168;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</font></p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">&#168;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">&#168;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">&#168;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="border-bottom:solid windowtext 3.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">
<hr size="3" width="100%" noshade color="#010101" align="left">
</font></b></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\106459\12-30363-1\task5728382\30363-1-ba.htm',USER='106459',CD='Jan  1 02:45 2013' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt .75in;text-indent:-.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.75in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 5.02.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</font></b></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b) Departure of Certain Officers and (c) Appointment of Certain Officers</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On December 28, 2012, the Board of Directors (the &#147;Board&#148;) of OvaScience, Inc., a Delaware corporation (the &#147;Company&#148;) elected Alison Lawton to the office of Chief Operating Officer of the Company, effective as of her first date of employment with the Company (the &#147;Effective Date&#148;), which is expected to be January 21, 2013.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Ms. Lawton, age 51, has been with Genzyme Corporation (&#147;Genzyme&#148;), a biopharmaceutical company that is now a subsidiary of Sanofi, also a biopharmaceutical company, for 21 years and most recently served as Senior Vice President and General Manager of Genzyme Biosurgery (now Sanofi Biosurgery Business Unit), a position she has occupied since April 2010.&#160; From May 2008 to April 2010, Ms. Lawton served as Senior Vice President, Global Market Access at Genzyme, and from November 2005 to April 2008, Ms. Lawton served as Senior Vice President, Global Regulatory Affairs, Corporate Quality Systems and Global Policy Programs at Genzyme.&#160; Ms. Lawton spent seven years from 1984 to June 1991 at Warner-Lambert/Parke-Davis, a pharmaceutical company and subsidiary of Pfizer Inc.&#160; Ms. Lawton currently serves as a director of Cubist Pharmaceuticals and of Verastem, Inc., both biopharmaceutical companies.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Also on December 30, 2012, the Company and Ms. Lawton entered into a Letter Agreement with respect to Ms. Lawton&#146;s employment.&#160; Pursuant to the terms of the Letter Agreement, Ms. Lawton&#146;s base salary will be $350,000 per year, and Ms. Lawton will be eligible to receive an annual discretionary bonus.&#160; Subject to approval by the Board, Ms. Lawton will receive options to purchase 368,892 shares of common stock of the Company with an exercise price equal to the fair market value of the Company&#146;s common stock on the date of grant.&#160; Ms. Lawton is also eligible for standard Company benefits and vacation time.&#160; Ms. Lawton will receive certain benefits upon termination of her employment by the Company without cause or by her for good reason.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On December 28, 2012, the Board also elected Christopher Bleck, the Company&#146;s current Chief Operating Officer, to the office of Chief Commercial Officer, effective as of the Effective Date, at which point Mr. Bleck will vacate the position of Chief Operating Officer.&#160; In addition, pursuant to and effective as of the Board&#146;s approval on December 28, 2012, Michael Flanagan ceased to serve as the Company&#146;s Treasurer, principal financial officer and principal accounting officer, and Mr. Bleck was appointed to fill those roles.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The full text of the press release issued in connection with these events is filed as Exhibit 99.1 to this Current Report on Form 8-K.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 9.01.&#160; Financial Statements and Exhibits</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">See the Exhibit Index attached hereto.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2<a name="PB_2_212538_7056"></a></font></p>
<div style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">
<hr size="3" width="100%" noshade color="#010101" align="left">
</font></b></div>
</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\106459\12-30363-1\task5728382\30363-1-ba.htm',USER='106459',CD='Jan  1 02:45 2013' -->

<br clear="all" style="page-break-before:always;">
<div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SIGNATURE</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">OVASCIENCE,   INC.</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date:&nbsp; January 2, 2013</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="46%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:46.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   Michelle Dipp, M.D., Ph.D.</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="46%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:46.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Michelle   Dipp, M.D., Ph.D.</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">President</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3<a name="PB_3_212744_5335"></a></font></p>
<div style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">
<hr size="3" width="100%" noshade color="#010101" align="left">
</font></b></div>
</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\106459\12-30363-1\task5728382\30363-1-ba.htm',USER='106459',CD='Jan  1 02:45 2013' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">EXHIBIT INDEX</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="8%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:8.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Exhibit&nbsp;No.</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="89%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:89.86%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Description</font></b></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:8.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.1</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="89%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:89.86%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Press   Release entitled &#147;OvaScience Appoints Alison Lawton to Chief Operating   Officer&#148; issued by the Company on January 2, 2013.</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4<a name="PB_4_212825_5796"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='4',FILE='C:\JMS\106459\12-30363-1\task5728382\30363-1-ba.htm',USER='106459',CD='Jan  1 02:45 2013' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a12-30363_1ex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>


<html>
<head>


  </head>
<body lang="EN-US">
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 99.1</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-weight:bold;"><img width="222" height="62" src="g303631mmi001.jpg" alt="GRAPHIC"></font></b></p>    </td>
<td width="50%" valign="bottom" style="padding:0in 0in 0in 0in;width:50.0%;">
<p align="right" style="margin:0in .25in .0001pt 0in;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">News Release</font></b></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">FOR IMMEDIATE RELEASE</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">OvaScience Appoints Alison Lawton to Chief Operating Officer</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CAMBRIDGE, Mass. &#151; January&nbsp;2, 2013 </font></b><font size="2" style="font-size:10.0pt;">&#151; OvaScience</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">SM</font><font size="2" style="font-size:10.0pt;">, (OTC: OVSC), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, announced today the appointment of Alison Lawton to Chief Operating Officer.&#160; In conjunction with this appointment, the Company&#146;s current Chief Operating Officer, Christopher Bleck, will assume the role of Chief Commercial Officer, leading Sales and Marketing.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;We are pleased to welcome Alison and believe that her extensive experience in directing global operations for Sanofi Biosurgery will enable her to make significant contributions to OvaScience as we prepare for commercialization in 2014,&#148; said Michelle Dipp, M.D., Ph.D., Chief Executive Officer of OvaScience. Alison&#146;s leadership of the autologous cell therapy business, including regulatory affairs, manufacturing and commercial in the U.S. and abroad, will be important to OvaScience&#146;s continued development of multiple therapies for infertility.&#148;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Ms.&nbsp;Lawton joins OvaScience from Sanofi Biosurgery (formerly Genzyme Biosurgery), where she was Senior Vice President and General Manager, responsible for three separate franchises, including surgical, cell therapy and regenerative medicine, and orthopedics.&#160; She has more than 28 years of global pharmaceutical and biotechnology experience, including 21 years at Genzyme Corporation and seven years in the U.K. at Warner-Lambert/Parke-Davis. Prior to Genzyme Biosurgery, Ms.&nbsp;Lawton was Senior Vice President of Global Market Access for Genzyme, which involved leadership across several of Genzyme&#146;s global functional organizations including regulatory affairs and corporate quality systems, policy programs, health outcomes and strategic pricing, patient safety and risk management, and biomedical process excellence and training. She served two terms as the industry representative on the U.S. Food and Drug Administration (FDA) Cell&nbsp;&amp; Gene Therapy Advisory Panel, and was past President and Chair of Board of RAPS (Regulatory Affairs Professional Society).&#160; Ms.&nbsp;Lawton is currently a Board member of Cubist Pharmaceuticals and Verastem,&nbsp;Inc. She holds a B.Sc.Hons. in Pharmacology from King&#146;s College London.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;OvaScience&#146;s unique approach to developing next-generation treatments for female infertility has the potential to improve the success of <i>in vitro </i>fertilization and offers new options for patients who are unable to undergo IVF,&#148; said Ms.&nbsp;Lawton.&#160; &#147;I am pleased to be joining a team that has already demonstrated its ability to turn major scientific discoveries into product candidates, and I am excited to be a part of bringing this to patients.&#148;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">About OvaScience</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">OvaScience (OTC: OVSC) is a life sciences company focused on the discovery, development and commercialization of new treatments for infertility. The Company&#146;s patented technology is based on the discovery of egg precursor cells (EggPC</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">SM</font><font size="2" style="font-size:10.0pt;">), which are found in the ovaries. By applying proprietary technology to identify and purify EggPCs, AUGMENT</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">SM</font><font size="2" style="font-size:10.0pt;">&#160;aims to improve egg quality</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105569\12-30363-1\task5728674\30363-1-mm.htm',USER='105569',CD='Jan  2 16:59 2013' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">and increase the success of <i>in vitro </i>fertilization (IVF). OvaScience&#146;s team of scientists, physicians and advisers includes recognized leaders in the field of reproductive medicine. For more information, please visit www.ovascience.com.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Forward-Looking Statements</font></b></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">This press release includes forward-looking statements about the Company&#146;s strategy, future plans and prospects, including statements regarding the development of the Company&#146;s product candidates, including AUGMENT</font></i><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">SM</font><i><font size="2" style="font-size:10.0pt;font-style:italic;">&#160;and OvaTure</font></i><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">SM</font><i><font size="2" style="font-size:10.0pt;font-style:italic;">. Any statements in this release about our strategy, plans, prospects and future expectations, financial position and operations, and other statements containing the words &#147;anticipate,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;plan,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;target,&#148; &#147;aim,&#148; &#147;potential,&#148; &#147;will,&#148; &#147;would,&#148; &#147;could,&#148; &#147;should,&#148; &#147;continue,&#148; and similar expressions, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: our expectations regarding the regulatory approvals required for AUGMENT; the science underlying our two product candidates, which is unproven; our ability to obtain, maintain and protect intellectual property utilized by our products;&#160; our ability to obtain additional funding to support our activities; our dependence on third parties; the successful development of, and ability to obtain regulatory approval for, our product candidates; our ability to commercialize our product candidates, including AUGMENT, on the timeline we expect, if at all; competition from others; and our short operating history; as well as those risks more fully discussed in the &#147;Risk Factors&#148; section of our most recently filed Quarterly Report on Form&nbsp;10-Q. The forward-looking statements contained in this presentation reflect our current views with respect to future events. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our view as of any date subsequent to the date hereof.</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Contact:</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Theresa McNeely</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Head of Corporate Communications</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">OvaScience,&nbsp;Inc.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">tmcneely@ovascience.com</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">617-299-7356</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105569\12-30363-1\task5728674\30363-1-mm.htm',USER='105569',CD='Jan  2 16:59 2013' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g303631mmi001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g303631mmi001.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!P@'!@H("`@+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!#`0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P``1"``^`-X#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#V:JU[?VNG
MP^;=3+&I.!GJQ]`.]32R+#$\KG"H"Q/L*X^.6*^6\U_5\M9P'$$(YW8[8[]O
MJ:J*N;TJ<6G.;M%?U8T9/&-JBF7[%=&!3\TI4!1^M7=+\2:3J[F.SO$:4#)C
M8X;'TKS>U&K_`!"U#>K[;6)L&/)6W@7/'RY^=B/\BMN3X2V0MF,6H3-<@?*6
M550GT(`R!73*C3CI.5F<LL1&HOW5/3O?_@'H5%>9^%M<UOPWKR^'=?$CPRN$
M@D<E@A)P,,>JGI7IE85*;INPJ=135PHHHK,T"BBB@`HHKRC6-<\0^,?%,^B:
M%<-;6L#,I*/LR%."S,.<9Z`5K2I.HWK9(RJ5%!=VSU>BO*G\`^--.4W-CKOF
MS+R$2X=2?^^N#^->F:<;@Z;:F[S]H,*>;GKNP,_K14IQBKQE<(3E+1QL6:**
MBN&E2VE:!`\JH2BDX#-C@?G61J2T5Q?@;6/%6I7]Y'KUHT4"+E&:'R]KY^Z/
M48S^5=I5S@X2Y61":FKH****@L****`"BBB@`HHHH`**;)(D2%W8*J]2:2*:
M*92T4BN`<$J<X-`%+7BXT.\V9!\L\CT[_I7!>+KEX/A[ID,#!1,Y+MNZ#G(Q
MWY->CW=NMW:2V[_=E0J?QKS#Q.LLGA6329OW=Q93!U7'WEZ=?QS71A[<ZOW-
MYQ<\%.,=T[_([+P#;)!X/LI%0*UPIE;\2<?I@5T=<-X#\3:>=/M],>=83M"P
M1R<$,!\RD]SG)'L<5W-16351W..BTX*QD>(-(L]2M5DN6$;P9*2$XP3P!G_>
MVGZ@5QWB+Q9XE\*ZG8?:?*FL)HT8@Q?-D`;UW>O?\:Z7Q;,MU%:Z%&Q,]_,A
M95_@B5@SL?0<8^IJ?Q=X?3Q)H$UG@"=?WD#G^%QT_`]/QK2G)1Y>?5,BI%N_
M)N:UK=0WMI%=6[AX9D#HP[@C-<"/&FLZWXX.D:$\*V*/M>5HMWRK]]\_H/PK
ME-.\:WNC>$K[0'5UN0YCA<]8E.=X/N.<?7VKL_`OAF31_"5S>LA6_OH&9?5%
MVG8/Z_\`ZJU=%44W+7HO\S)575:4?5_Y&;K_`(^UC4]:;1O"D9.UBGFJ@9Y"
M.I&>`H]:$U7X@>%PM[K$'VZP!!F`*,R#N<KR/QR*K_!YK47^HJ^!=F--F>NS
M)W8_'%>HW+0+:RM<E1`$/F;^FW'.?;%%64:4O9J*:_$*<95(^T<M?P.!\">,
MM6\1>)+FUNY4:U6)I(U$84CYAC)'L:YO4H-;^'WBV?4[>$O;3.Q61E)CD1CG
M:Q'0U/\`"HQ?\)A>&+B+[.^S/]W>,?I7KK)%<1%75)8W'((!#"JJS5&JTEHU
ML*G!U::;>J9QV@_$[1M6=(+P-I]PW`\PYC)]F[?CBN@\0:]:^'=(DU&ZRRK@
M1HIYD8]`*X?XD>#M(LM(?6+")+25'57C3A),G'`['Z>]<WKEW>WGP[T%YW9T
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M^]_4Z"[UWQWX-FAGUETO;21L'.&4^VX`$'ZUO>,?&5UI_AW3-5T62,+>MUD3
M=QMSCZYK.O\`P)XQU2U-K?>)8;B$D$HX;&1T[5G>.-(GT'P)HVFW$R3207#@
MN@('()[_`%J4J4Y1VO?H4W4A&6]O,MQ:UX_\464=QI$"VMLJ`&7Y5,S#[Q&[
MMGT_.H/#_CKQ!IOB./1_$69%DD$3^8@5XB>AR.HZ5W_A-0/"6E```?98^GTK
MSSXA`#XC::0`"5@S[_.:FFXSE*FXJVHYJ4(JHI.^AU/CCQR/#(2RLXUFOY5W
M8?[L:]B?4GL*YVW7XHW\8O4E:)6^98W\M,C_`'2/YU2U=HD^,BMJ./(%S%@O
MTQL&W\,UZ_42<:,(VBFVKZEQ3JRE=M)=CCSXKU#P_P"#5O\`Q%;_`/$R,C1)
M"`%\PYX/'&,<DBN=M+GXD>([?^U+.=+:W?F*,;4##V!!)'N:?\9/-WZ5U\K$
MO_?7R_TJ;2_#OC.[TJUGLO%D0MGB4Q*N["KC@=.W2M(J*IJ>EWW(DY.HX:V7
M8N>#?&-YJ^H3^'?$,"B\4,`=NW?C[RL/7OQ7<P6L%JI6"%(@QR0HQDUP6C>`
M-;L_%=OKFH:M;W+HY:0@-N?Y=OI7H5<U?DYO<V.BCS\OOA65K.@6VL)EF,4P
M&/,49R/0CN*U:K_;K?\`M$:?O/V@P^=MP?N9QG/UK!7Z'3"I*G+FB[,\QU+X
M>:W83M+IC13VS'<\><DGL2IQGZCFM*QU/QK;6XLK30XDSG][()6P3W`8\?3.
M*]$HKH^L-JTE<YY4ES.4=/0Y_0?#9LKB34]0GENM1G`\R60CI_=`'``]!704
M45A*3D[LTC%15D</K'P^BU+QM;:J`HLG_>7<?]YUZ<>C=_H?6NW`P,#I45U=
M06-L]S<R".),;F()QDX_K4M5*<I)7Z"C",6[=3S;Q%\.M2@U@ZOX7G$3LQ<Q
M;]C(QZ[3TP?0TU/#/CKQ"8[7Q!J/V>P!'F*KKN<>F$Z_C7IE94OB*PBU1M-Q
M</<(RJWEV[LJENF6`P.M;1KU&K6NUUMJ8NA33O>U_N.5\%^!M2\.Z_=7=R\!
MMI(GCC".6;!8$9X]!6</#/C_`,/.T6BZB+FUR=BAUP!_NOP/PKU"HC<0K<+;
MF11,REU3/)48!./Q%3]8FVVTF/V$$DD['ETG@[QOXHN(QX@O!#;HV?F=3CW"
M)QGZUW-WX1TRZ\+IX?VLEO&H$;C[R,/XOKG.?J:M/XBTJ.0HUT.$D<G:<`1D
M!^W8D5=BNH)Y)(HI5=XL;U!Y7(R,^F11.K4=M+6'"E35^MSRZW\(^//#,LD>
MB7:2P,<_)(NT^Y1^`:Z;POI_B\2WLOB.Z#K+!LBBWJ0K>N%&!76S2K!`\SAB
MJ*6(52QP/0#K6+'XST>03,&NE6`$RL]K(H3`S@DC@\]*IU9U$_=7K8E4H4W\
M3]+F-\/_``?J?ABZOI+]X&6X10GE.3T)ZY`]:R]>^'&I6VL-JWABY$3,Y?RM
M^QHV/7:>A'L:]*!R`1WI:GZQ-3<^Y7L(<JCV/,18?%*Z40R7BP+TW^9&I_-1
MFK^O>"-9U+PGINEK>17%W;2L\TTKMALY[D$GK7?T4?6)7322MY!["-FFVRAH
M=E+IVA65E.5,L$"1N5.1D#'%<GXL\&:IK?BVSU6U>W$$"QA@[D-\K$G`Q79V
M=]!?QO);N66.5XF)!&&4E6'YBJFI:_9:9<+;3">69D\SRX(6D94SC<<#@9J8
M3G&;:W*G&$H)/8Q/&W@6+Q.$NK:58+^)=H9A\LB^C?T-<W;Z7\3["$6<%SNB
M485FEC?`]BW->H1R++$LB9VN`PR,<'VJ*UN[>]A\ZVD$D>XKN`(Y!P1^8JHU
MYQCRM)I=R948RES)V?D<N_A&\USP;%IOB"ZWZBCM(MP#OV-DX],C'&*Y>S\-
M?$/PZ&MM*N4>WW'`25"GU"OTKU>BB.(DKJR:[!*A%V=W<X+0=!\:S:W;7^OZ
MF!;V[%OLXDSO.".B\=Z[VBBLIS<W=FD(*"L@KC/%R7JZG=36:W"O_9@19(%.
M03.F0".^,UV=%$)\CN$X\RL<5=:)*MYK$$5UJ@@@LDGM@+F0_OB'R0<\GY5X
MZ<].:S6NDGN-2.JS:L9Q#";9;8RX64PJ3@+P&W=FX_6O1ZK6]C!:W-S<1*1)
M=.'E).<D`*/IP*U5;N9NCV..A@UZ6WU6[D:[.J6UK!Y"!V";S$-Y5?NLV<^H
MS1:1#4+R.ST2_P!5$4MLXO)9VD_=28!1LOT?=U`XQFNZI*7MO(?LO,X:XG\0
M7^D7NH7*7%K-:(EK'!"3^\D#KYDN!U!Z#VS1=6U^+34=46;4?MD&K%;=1(^W
MRO,48"="I!/:NZHH]MV0>R\S@-,E^V>,=DU^&-O>2L)6N7*W(P=J(GW?ESC@
M_P`)K6BLK\Z]KMW;7%Q$R%#%#M'ES-Y7&21SSZ&KUMX5L;6>%EFNF@MI3-!;
M/+F*)SGD#&>YQD]ZVZ<ZJO[O84*;MJ>6PW&JG2KF2+4;C[:;)A/;JEP93)D<
MG=\JL#G[N,YXK:U'3;#2_$6G2W4NH);26LBF43RN?,W(0,C)&>>.AQ7<44.O
M=[`J.FYYW=_VF7EN`ET9H[745C?8VX?O%V`?@.*MP6%J?%.JVUS<W]M<7BQ&
MW9))!NS'\QR..#Z]*[FFR)YD;)N9=P(RIP1]*7MNE@]CYG+^&I]5U>]^T7\A
M6+3`UK^[?Y;F8'#2>XP!@>I/I5?4+>X?1/%B+#+NEG/E@(26^1.1ZUU5C8V^
MFV45G:ILAA7:JYS^9[FIZ7M+2ND5[/W;-G":Y97VEO=0:;<:DT<UC&['S7D(
MD\]%)!YP=I;('Y5/J4-O8:L]KJ=QJ<.G);@V;022MND))?++DE^F`>,5VM%/
MVSZB]EV.%L]8U'3]PUIKM9KC2T\@>4S%I`TG91@/@IFLF6XN+AK.RO;]UDEL
M[4M-+<R1BU(QO5U'!9_]K%>H5BWGA>RO+BXD:>ZCCNR#<P1RXCF(`'(QGH`#
M@C-5&K&]VK$2I2M9.YST6FSVUF^HV[7T=RNM.%C5WV>49R"-G0J5).<>^:O^
M*9+.VO\`[7#?W=AJJ08C:&%I%G7)(0K@AN<^A&:ZL*%``&`!@"EJ/:W=V:>R
MLK(XBWN7N-79O$SWUI<.L)M(86D6+E1NQLZMOR#GMBLNXN-7,=JE]<3P6;&Y
M_>2^<H\SS2%W&/YA\N-N>*]+HJE6MT)=*_4X."QOM0M]1>ZU#4)FMM/A:VDB
M:2$/)L<E@O!)X'!_*I+.X$NI9\07&H13E8#9(ID6-@44D_)P6WYR&KN**7MO
M(?LO,\]T"?4WURV:]U!XKWSW%S;LDY+CG"X_U84<$$8Z5Z%1145)\[O8J$.1
$6N?_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
